A clinical study report is mostly a description of things that already exist. The tables are produced. The analyses are run. The protocol said what would be done and the statistical analysis plan said how. Much of the authoring effort goes into restating that material in prose, consistently, across several hundred pages.
That makes CSR authoring one of the better candidates for AI assistance in regulated writing, and also one where the failure mode is specific and serious: a statement in the text that the tables do not support.
This is how we approach CSR authoring, and the constraint we design around.
The only failure that really matters
Most concerns about AI in regulatory writing are about tone and polish. Those are real and they are not the risk. The risk is a sentence that sounds correct, reads fluently, and is not supported by the data it refers to.
This is worse than an obvious error, because an obvious error gets caught. A plausible, fluent, wrong statement survives review — particularly on page 180, in a section a reviewer has read four similar versions of.
So the design question is not how to make the writing good. It is how to make every factual statement checkable against its source without the reviewer having to go and find the source. If verification requires leaving the document and hunting for a table, verification will degrade, and it will degrade exactly where attention is thinnest.
Source traceability as a working requirement
The requirement that follows is that each factual statement carries its provenance — which table, listing or dataset it came from — so a reviewer can confirm it in place. That is what clinical documentation is built for, and it changes the review from reading for plausibility to checking against a source.
It also changes what happens when the data changes, which it does. A re-run analysis, a corrected dataset, a late query resolution. Where statements are linked to sources, the statements affected by a changed table are identifiable. Where they are not, somebody re-reads the document and hopes.
This is the same problem as traceability in validation, and it has the same answer: a derived view cannot disagree with the underlying records, and a document maintained by hand reports whatever it was last told.
What AI drafts well, and what it must not touch
The split is cleaner in a CSR than in most document types, because the ICH E3 structure separates description from interpretation fairly explicitly.
Drafts well: demographic and baseline summaries, disposition narratives, protocol deviation descriptions, exposure summaries, the descriptive portions of efficacy and safety results, prose restating tables, and consistency work across sections — which is where human authors most often slip, because the same number appears in four places.
Must not touch: the clinical interpretation, the benefit-risk discussion, the conclusions, and causality judgements on individual events. These are not drafting problems. They are the reason a qualified medical author is named on the document.
A system that drafts the first list and leaves the second is working correctly. One that proposes conclusions is doing something categorically different and should be assessed as such.
Consistency is where the time actually goes
Ask a medical writer what consumes a CSR cycle and the answer is rarely the first draft. It is reconciliation: the same figure appearing in the synopsis, the body, a table and the discussion, and making all four agree after the third data refresh.
This is mechanical work that humans do badly — not through carelessness but because it requires holding several hundred pages in mind simultaneously. It is also the work most likely to produce a finding, because an inconsistency between the synopsis and the body is the kind of thing a reviewer notices immediately and draws conclusions from.
Automating consistency checking against source rather than against other prose is a larger practical gain than automating the first draft, and it is less discussed because it is less impressive to demonstrate.
Validating the system
A CSR authoring tool producing content for a regulatory submission is a system whose output enters the regulated record, so it is validated on the usual terms, with the AI-specific additions.
What we would expect to see: a stated intended use including what it is not for, acceptance criteria defined before evaluation, an evaluation set with known-correct outputs that gates releases, and a specific test for the failure that matters — unsupported statements — rather than only an aggregate quality measure. An average accuracy figure will not surface an occasional fabrication, and an occasional fabrication is the whole risk.
Plus the elements the draft EU GMP Annex 22 describes, which is not binding today but is the clearest statement of direction: model governance, safeguards on outputs, a named human review role, drift monitoring, and a fallback. AI validation services is the practice and what sponsors ask about AI in clinical writing covers what sponsors ask.
Where to start
Not with the full report. Start with the sections that are purely descriptive and high-volume — disposition, demographics, exposure, protocol deviations. The review burden is low, the source is unambiguous, and a writer can judge the output quickly.
Then consistency checking across the whole document, which is the highest-value step and the safest. Leave the discussion and conclusions alone, permanently.
TraceDraft is the product, with HITL reviews as the review gate and safety narratives for the related narrative work. medical writing is the practice, and book a demo if you want to see it run against one of your own study reports rather than a demonstration dataset.
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.
